title: Medroxyprogesterone increases basal temperature: a placebo-controlled crossover trial in postmenopausal women.
abstract: OBJECTIVE
  To assess whether temperature is increased by medroxyprogesterone (MPA) and thus whether basal temperature records could be used to determine ovulation during cyclic MPA therapy.
  
  
  METHODS
  A 2-month double-blind placebo-controlled crossover trial in which oral basal temperature was measured daily.
  
  
  METHODS
  Normal human volunteers in an academic medical environment.
  
  
  METHODS
  Eleven postmenopausal women not taking gonadal hormones.
  
  
  METHODS
  Medroxyprogesterone acetate (10 mg/d) or placebo, calendar days 16 to 25, with crossover.
  
  
  METHODS
  Comparison of mean temperature days 17 to 26 during MPA versus placebo; comparison of differences between temperatures days 7 to 16 and 17 to 26 in MPA versus placebo months; and analysis for a significant monthly thermal shift.
  
  
  RESULTS
  The mean temperatures during MPA treatment averaged 0.27 degrees C higher than during the placebo phase and showed a significant change from pretreatment to "treatment" phases during MPA but not during placebo cycles. Eight of the MPA and one of the placebo cycles showed a shift from lower to higher temperatures days 16 to 25.
  
  
  CONCLUSIONS
  Medroxyprogesterone acetate has a physiological progesterone-like thermal effect. Therefore basal temperature data cannot reliably indicate ovulation during cyclic MPA administration.
authors.affiliation: Department of Medicine, University of British Columbia, Vancouver, Canada.
authors.forename: J C
authors.initials: JC
authors.lastname: Prior
authors.forename: D W
authors.initials: DW
authors.lastname: McKay
authors.forename: Y M
authors.initials: YM
authors.lastname: Vigna
authors.forename: S I
authors.initials: SI
authors.lastname: Barr
mesh_terms: D000328:Adult; D001831:Body Temperature / Q000187:drug effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause / Q000502:physiology*; D011446:Prospective Studies
chemical_list: D010919:Placebos; D017258:Medroxyprogesterone Acetate